Literature DB >> 19576339

Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]).

Andreas Wolfgang Schoenenberger1, Richard Kobza, Peiman Jamshidi, Michel Zuber, Antonio Abbate, Andreas Ernst Stuck, Matthias Pfisterer, Paul Erne.   

Abstract

The occurrence of sudden cardiac death (SCD) in patients with silent ischemia after myocardial infarction (MI) and the factors facilitating SCD are unknown. This study aimed to determine the factors facilitating SCD in patients with silent ischemia after MI. In the Swiss Interventional Study on Silent Ischemia Type II (SWISSI II), 201 patients with silent ischemia after MI were randomized to percutaneous coronary intervention (PCI) or medical management. The main end point of the present analysis was SCD. Multivariable regression models were used to detect potential associations between baseline or follow-up variables and SCD. During a mean follow-up of 10.3 +/- 2.6 years, 12 SCDs occurred, corresponding to an average annual event rate of 0.6%. On multivariate regression analysis, the decline in the left ventricular ejection fraction (LVEF) during follow-up was the only independent predictor of SCD (p = 0.011), other than age; however, the baseline LVEF was not. The decline in LVEF was greater in patients receiving medical management than in those who had received PCI (p <0.001), as well as in patients with residual myocardial ischemia or recurrent MI compared with patients without these findings (p = 0.038 and p <0.001, respectively). Compared with medical management, PCI reduced the rate of residual myocardial ischemia (p <0.001) and recurrent MI (p = 0.001) during follow-up. In conclusion, patients with silent ischemia after MI are at a substantial risk of SCD. The prevention of residual myocardial ischemia and recurrent MI using PCI resulted in better long-term LVEF and a reduced SCD incidence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19576339     DOI: 10.1016/j.amjcard.2009.03.019

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study.

Authors:  Andreas W Schoenenberger; Renate Schoenenberger-Berzins; Christoph Auf der Maur; Paolo M Suter; Athanasios Vergopoulos; Paul Erne
Journal:  Clin Res Cardiol       Date:  2011-11-05       Impact factor: 5.460

2.  Utility of electrophysiological studies to predict arrhythmic events.

Authors:  Gabriela Hilfiker; Andreas W Schoenenberger; Paul Erne; Richard Kobza
Journal:  World J Cardiol       Date:  2015-06-26

3.  Progression of coronary artery disease during long-term follow-up of the Swiss Interventional Study on Silent Ischemia Type II (SWISSI II).

Authors:  Andreas W Schoenenberger; Peiman Jamshidi; Richard Kobza; Michel Zuber; Andreas E Stuck; Matthias Pfisterer; Paul Erne
Journal:  Clin Cardiol       Date:  2010-05       Impact factor: 2.882

4.  Ultrasound-assessed non-culprit and culprit coronary vessels differ by age and gender.

Authors:  Andreas W Schoenenberger; Nadja Urbanek; Stefan Toggweiler; Andreas E Stuck; Thérèse J Resink; Paul Erne
Journal:  World J Cardiol       Date:  2013-03-26

5.  Cardiovascular risk evaluation and prevalence of silent myocardial ischemia in subjects with asymptomatic carotid artery disease.

Authors:  Marco Matteo Ciccone; Artor Niccoli-Asabella; Pietro Scicchitano; Michele Gesualdo; Antonio Notaristefano; Domenico Chieppa; Santa Carbonara; Gabriella Ricci; Marco Sassara; Corinna Altini; Giovanni Quistelli; Mario Erminio Lepera; Stefano Favale; Giuseppe Rubini
Journal:  Vasc Health Risk Manag       Date:  2011-03-04

6.  Outcome of prolonged ventricular fibrillation and CPR in a rat model of chronic ischemic left ventricular dysfunction.

Authors:  Xiangshao Fang; Lei Huang; Shijie Sun; Max Harry Weil; Wanchun Tang
Journal:  Biomed Res Int       Date:  2013-12-17       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.